Skip to main content
Article
Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016
Cancer Medicine (2019)
  • Jimena Ylescas‐Soria, National Autonomous University of Mexico
  • Alfredo H. de la Torre‐Lujan, Department of Hematology National Cancer Institute Mexico City Mexico
  • Luis A. Herrera, National Autonomous University of Mexico
  • Daniela Miranda, National Autonomous University of Mexico
  • Flavio Grimaldo, Department of Hematology Instituto Nacional de Cardiología "Ignacio Chávez" Mexico City Mexico
  • Silvia Rivas, Department of Hematology National Cancer Institute Mexico City Mexico
  • Eduardo Cervera, National Autonomous University of Mexico
  • Abelardo Meneses‐García, National Autonomous University of Mexico
  • Fidias E. Leon-Sarmiento, University of Pennsylvania
  • Diddier Prada, National Autonomous University of Mexico
Publication Date
May 2, 2019
DOI
10.1002/cam4.2201
Citation Information
Jimena Ylescas‐Soria, Alfredo H. de la Torre‐Lujan, Luis A. Herrera, Daniela Miranda, et al.. "Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016" Cancer Medicine (2019)
Available at: http://works.bepress.com/fidias-leon-sarmiento/2/